传奇生物首席执行官黄颖博士表示： “西达基奥仑赛CARTITUDE临床开发计划的研究结果将为得益于该一次性治疗的广大患者提供重要见解。我们很高兴与血液学和肿瘤学界分享我们的最新资料，同时我们致力于为患者带来新的希望，并争取朝一日能治愈多发性骨髓瘤。”Glonghui May 24 | Kingsley Biotechnology (01548.HK) issued an announcement. On May 23, 2024 local time, Legendary Biotech (NASDAQ: LEGN) announced in Somerset, New Jersey, USA, that it will evaluate CARVYKTI in the CARTITUDE clinical development plan(cilta-cel, sidachiolense) The latest information on treating patients with multiple myeloma will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology Association (EHA) Conference.
Cohort D from the phase 2 study CARTITUDE-2 investigated a single infusion of CARVYKTI in patients who did not achieve complete remission after first-line autologous stem cell transplantation (ASCT) treatmentThe results of maintaining treatment with or without lenalidomide will be presented for the first time in the form of an oral report at the ASCO annual meeting and again at the EHA meeting.
Data from the CARTITUDE-4 subgroup analysis of the Phase 3 study will be presented in the form of an oral report at the ASCO annual meeting. This subgroup analysis compared CARVYKTI Efficacy with two standard treatments in patients with functional high-risk multiple myeloma. Additionally, the results of the CARTITUDE-4 subgroup analysis based on cytogenetic risk will be presented in poster form at the EHA conference.
Dr. Huang Ying, CEO of Legendary Biosciences, said, “The findings of the Sidakiolense CARTITUDE clinical development plan will provide important insights for a large number of patients who have benefited from this one-time treatment. We are excited to share our latest information with the hematology and oncology community, and we are committed to bringing new hope to patients and seeking a cure for multiple myeloma one day.”
